Sign In
Buy JAZZ
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival
02:18pm, Friday, 20'th Jan 2023
Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.
Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmaceuticals
08:07am, Thursday, 19'th Jan 2023
Shares of Zymeworks Inc. ZYME, rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ, -0.58% said their experimental cancer drug had an overall survival rat
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher
05:25am, Wednesday, 11'th Jan 2023
There are still plenty of growth opportunities left for these businesses.
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.
05:30am, Saturday, 07'th Jan 2023
These stocks look cheap if you take a long-term view.
2 Cannabis Stocks to Buy for the Long Haul
07:07am, Saturday, 31'st Dec 2022
Don't give up on this sector too quickly.
Why Is Jazz (JAZZ) Up 0.1% Since Last Earnings Report?
12:48pm, Friday, 09'th Dec 2022
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Data from six abstracts to be presented, including new long-term Phase 3 results and two real-world analyses of U.S. caregiver-reported seizure and non-seizure outcomes in patients prescribed Epidiole
Want to Double Your Money? Buying These Stocks Could be a Genius Move
06:00am, Monday, 28'th Nov 2022
These stocks are undervalued considering their long-term growth potential.
Prediction: This Growth Stock Could Double in 2023
09:45am, Thursday, 24'th Nov 2022
The next year should be a busy one for this drugmaker.
Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option
01:32pm, Monday, 21'st Nov 2022
Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
3 Top Cannabis Stocks to Buy in November
06:05am, Sunday, 20'th Nov 2022
These solid performers are managing to grow revenue in a difficult environment.
Jazz Pharmaceuticals: Q3 Results, Pipeline Cleanup, And An Unhappy FTC
08:00am, Tuesday, 15'th Nov 2022
Jazz Pharmaceuticals reported solid Q3 results and raised the full-year guidance by $50 million at the midpoint. Xywav is overtaking Xyrem as the company's top-selling product, thanks in part to a str
Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales
12:47pm, Thursday, 10'th Nov 2022
Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q3 2022 Results - Earnings Call Transcript
11:30pm, Wednesday, 09'th Nov 2022
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Andrea Flynn - VP and Head, IR Bruce Cozadd - Chairman and CEO Dan Swisher - P
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates
06:48pm, Wednesday, 09'th Nov 2022
Jazz (JAZZ) delivered earnings and revenue surprises of 9.53% and 0.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
